Related Experiment Videos
[Therapeutic effects of human urinary trypsin inhibitor on acute experimental pancreatitis]
Abstract:
Therapeutic effects of human urinary trypsin inhibitor (MTI) on acute pancreatitis were examined. MTI potently inhibited not only proteases such as trypsin or alpha-chymotrypsin, but also inhibited lipase or creatine phosphokinase which are considered to be related to pancreatitis. Although gabexate mesilate (gabexate) and aprotinin also strongly inhibited trypsin, their inhibition spectra against pancreatic enzymes were narrower and aprotinin also strongly inhibited trypsin, their inhibition against pancreatic enzymes were narrower than MTI. MTI inhibited proteases released from pancreatic slice by trypsin more potently than gabexate or aprotinin. The therapeutic effects of MTI on experimental acute trypsin-induced pancreatitis in dogs or rats were stronger than those of gabexate or aprotinin. These results suggest that MTI may suppress pathogenesis and development of pancreatitis in several ways, for example, by directly inhibiting trypsin and by inhibiting tissue-damaging enzymes released from the pancreas by stimulation with trypsin.
Insights
Human urinary trypsin inhibitor (MTI) shows potent therapeutic effects against acute pancreatitis. MTI effectively inhibits various enzymes involved in pancreatitis, outperforming other inhibitors in experimental models.
Area of Science:
- Biochemistry
- Pharmacology
- Gastroenterology
Context:
- Acute pancreatitis is a severe inflammatory condition of the pancreas.
- Current treatments have limitations in managing the complex enzymatic cascade involved.
- Identifying novel therapeutic agents with broader inhibitory profiles is crucial.
Purpose:
- To evaluate the therapeutic efficacy of human urinary trypsin inhibitor (MTI) in experimental models of acute pancreatitis.
- To compare the enzyme inhibition spectrum of MTI with existing therapeutic agents like gabexate mesilate and aprotinin.
Summary:
- Human urinary trypsin inhibitor (MTI) demonstrated potent inhibition against a wide range of enzymes implicated in acute pancreatitis, including trypsin, alpha-chymotrypsin, lipase, and creatine phosphokinase.
- MTI exhibited a broader inhibition spectrum compared to gabexate mesilate and aprotinin.
- In experimental models of trypsin-induced pancreatitis in dogs and rats, MTI showed superior therapeutic effects than gabexate mesilate and aprotinin.
- MTI's mechanism may involve direct trypsin inhibition and suppression of other tissue-damaging pancreatic enzymes.
Impact:
- MTI presents a promising therapeutic candidate for acute pancreatitis due to its broad-spectrum enzyme inhibition.
- These findings suggest MTI could offer a more effective treatment strategy by targeting multiple pathways in pancreatitis pathogenesis.
- Further research into MTI's clinical application could lead to improved patient outcomes in managing acute pancreatitis.